Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application
Corcel Drills Cu-Au Skarn, Indications of Nearby Porphyry Cu-Au Center at the Yuma King Project, Arizona
RETRANSMISSION: QIMC Reports Record 23.5% Natural Hydrogen Within the First 300 Metres of Ongoing DDH-26-05 and Observations Consistent with Free Gas at Bennett Hill at 164 Metres
TomaGold Provides Corporate Update on Berrigan Mine Drilling, Geophysical Surveys and Regional Sampling Programs
